This study will seek to determine the maximum tolerated dose (MTD) and toxicity of the combination of doxorubicin, ICRF-187, IL-3 and GM-CSF in patients with untreatable or refractory solid tumors and assess the ability of the cytokine regimen to maintain chemotherapy doses over several cycles.
Showing the most recent 10 out of 470 publications